Laboratory of Precision and Nanomedicine develops smart cancer therapeutics with increased potency and decreased side effects.

Our mission is to change the perception of cancer as being a largely incurable disease. We use in vivo peptide phage display screens to identify homing peptides that bind to specific targets in the vasculature. Corresponding synthetic peptides are explored for targeting drugs, biologicals, and nanoparticles into tumors to increase their therapeutic index. We focus on development of novel diagnostic tests and therapeutics for the early detection and precision treatment of solid tumors (glioblastoma, and breast, prostate ovarian, prostate, and colorectal carcinoma). Our lab is also at the forefront of development of next generation peptidic shuttles capable of efficient and high capacity payload delivery across the blood brain barrier.

News

  • Looking forward to exciting 2024 Looking forward to exciting 2024

    Written on Saturday, 10 February 2024 11:07

    Our lab is buzzing with activity, fueled by new grants and promising projects set to unfold in 2024. We eagerly await the publication of groundbreaking…
  • Success: Transcan-3 Grant Awarded to "ReachGLIO" Project Success: Transcan-3 Grant Awarded to "ReachGLIO" Project

    Written on Friday, 22 December 2023 00:13

    We are thrilled to share the exciting news of our latest achievement in securing European funding. The consortium led by Prof. Pilar Sanchez Gomez from…
  • Advancing Innovation: IP Protection Milestones in 2023 Advancing Innovation: IP Protection Milestones in 2023

    Written on Friday, 22 December 2023 00:10

    In 2023, our laboratory has been actively engaged in securing intellectual property (IP) for the innovative inventions developed within our research initiatives. We are pleased…

EMBO

ERC

wellcome trust

  

 

Recent publications

Images